Academic Journal
أعرض في EDS

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

التفاصيل البيبلوغرافية
العنوان: Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)
المؤلفون: Elizabeth M. Swisher, Tanya T. Kwan, Amit M. Oza, Anna V. Tinker, Isabelle Ray-Coquard, Ana Oaknin, Robert L. Coleman, Carol Aghajanian, Gottfried E. Konecny, David M. O’Malley, Alexandra Leary, Diane Provencher, Stephen Welch, Lee-may Chen, Andrea E. Wahner Hendrickson, Ling Ma, Prafull Ghatage, Rebecca S. Kristeleit, Oliver Dorigo, Ashan Musafer, Scott H. Kaufmann, Julia A. Elvin, Douglas I. Lin, Setsuko K. Chambers, Erin Dominy, Lan-Thanh Vo, Sandra Goble, Lara Maloney, Heidi Giordano, Thomas Harding, Alexander Dobrovic, Clare L. Scott, Kevin K. Lin, Iain A. McNeish
المصدر: Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
بيانات النشر: Nature Portfolio
سنة النشر: 2021
المجموعة: Directory of Open Access Journals: DOAJ Articles
مصطلحات موضوعية: Science
الوصف: The identification of biomarkers of response to PARP inhibitors can enable selection of appropriate ovarian cancer patients for treatment. In this study, the authors report clinical results and exploratory biomarker analyses from the ARIEL2 phase 2 clinical trial on the safety and efficacy of the PARP inhibitor rucaparib in patients with recurrent ovarian cancers
نوع الوثيقة: article in journal/newspaper
اللغة: English
تدمد: 2041-1723
Relation: https://doi.org/10.1038/s41467-021-22582-6; https://doaj.org/toc/2041-1723; https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
DOI: 10.1038/s41467-021-22582-6
الاتاحة: https://doi.org/10.1038/s41467-021-22582-6
https://doaj.org/article/4c0bb318d2464bacb5fcd01f6ceefda3
رقم الانضمام: edsbas.EE8B7A86
قاعدة البيانات: BASE
الوصف
تدمد:20411723
DOI:10.1038/s41467-021-22582-6